Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 8/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | ANPEP | P15144 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621511 | 0.85 | ACP3 (0.48) | ACP3ANPEPERAP1ERAP2 | |
| SCHEMBL8618661 | 0.82 | POLB (0.48) | ACP3MTNR1AMTNR1B | |
| SCHEMBL8620902 | 0.79 | NR1I2 (0.42) | LAP3 | |
| SCHEMBL8620665 | 0.75 | ACP3 (0.46) | ACP3ANPEPERAP1ERAP2SRC | |
| SCHEMBL8619710 | 0.75 | S1PR2 (0.58) | ACP3ANPEPERAP1ERAP2 | |
| SCHEMBL8621508 | 0.75 | FDFT1 (0.49) | ACP3ANPEPERAP1ERAP2 | |
| SCHEMBL8625400 | 0.75 | S1PR2 (0.58) | ACP3ANPEPERAP1ERAP2 | |
| SCHEMBL8621105 | 0.74 | MMP13 (0.43) | ACP3SRC | |
| SCHEMBL8623419 | 0.73 | SLC6A4 (0.46) | ACP3SRC | |
| SCHEMBL8621507 | 0.73 | SRC (0.38) | ACP3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |